| | |
|---|---|
| **Inclusion criteria** | Patients with COPD, GOLD C or D and FEV1<65%;<br>AHRF (pH<7,35 and PaCO2≥45mm Hg (≥6kPa) treated more than 24h with Ventilation (non-invasive or invasive);<br>48h to 2 weeks with pH>7.35, and PaCO2>45 (>6kPa) after NIV withdrawal, during daytime at rest without oxygen or ventilatory support (or with O2 if patients are not able to avoid O2 with immediate desaturation below 80%). |
| **Exclusion criteria** | Patient treated with chronic NIV or CPAP device, with ongoing treatment;<br>Primary diagnosis of restrictive lung disease causing hypercapnia i.e. obesity hypoventilation and chest wall disease, however these patients will be included if the FEV1/FVC ratio is <60% and the FEV1 <50% if the predominant defect is considered to be obstructive by the center clinician;<br>BMI > 35 kg/m2;<br>Sedative medication causing hypercapnia (> 3 drugs or more than 20mg of morphin/day);<br>Polygraphic diagnosis of Obstructive Sleep Apnoea Syndrome (AHI>30/h (French criteria);<br>Cognitive impairment that would prevent informed consent into the trial<br>Pregnancy;<br>Tobacco use < 10 pack-year;<br>Psychiatric disease necessitating anti-psychotic medication, ongoing treatment for drug or alcohol addiction, persons of no fixed abode post-discharge;<br>) Unstable coronary artery syndrome;<br>) Age <18 years;<br>) Inability to comply with the protocol;<br>) Expected survival<12 months due to any situation other than COPD disease;<br>) Duration of ICU stay>10 days;<br>) No affiliated to national health insurance. |